Crispr Therapeutics announced that Rodger Novak, President and Chairman of the Board of CRISPR Therapeutics, has elected to leave the company after nearly a decade of service, effective as of September 15. As of that date, Samarth Kulkarni, CEO, will succeed Novak as Chairman of the Board and will continue serving as CEO of the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Biotech Alert: Searches spiking for these stocks today
- Crispr Therapeutics upgraded to Buy after 30% selloff at Citi
- Crispr Therapeutics upgraded to Buy from Neutral at Citi
- Crispr Therapeutics price target lowered to $110 from $123 at Chardan
- Crispr Therapeutics reports Q2 EPS (98c), consensus ($2.12)